BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease (DKD), hitting a primary endpoint of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback